Disc Medicine Completes Enrollment in Phase 3 APOLLO Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IRON?
Source: Newsfilter
- Clinical Trial Progress: Disc Medicine has completed enrollment of 183 patients in the Phase 3 APOLLO trial for EPP, with topline data expected in Q4 2026, a move that not only meets patient and physician demand but also lays the groundwork for future FDA submissions.
- ASCO Presentation: At the upcoming ASCO Annual Meeting, Disc will present updated data from the Phase 2 trial of DISC-0974 in 61 patients with MF anemia, which is expected to enhance the company's influence in the oncology space and prepare for subsequent FDA meetings.
- Strong Financial Position: As of March 31, 2026, Disc's cash and cash equivalents totaled approximately $730 million, projected to fund operations into 2029, demonstrating robust financial resilience that supports ongoing R&D initiatives.
- Increased R&D Spending: The R&D expenses for Q1 2026 were $45.9 million, significantly up from $27.8 million in Q1 2025, reflecting strategic investments in advancing clinical trials and expanding the team, despite resulting in a net loss of $63.5 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 67.640
Low
100.00
Averages
120.20
High
154.00
Current: 67.640
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Completes Enrollment in Phase 3 APOLLO Study
- Clinical Trial Progress: Disc Medicine has completed enrollment of 183 patients in the Phase 3 APOLLO trial for EPP, with topline data expected in Q4 2026, a move that not only meets patient and physician demand but also lays the groundwork for future FDA submissions.
- ASCO Presentation: At the upcoming ASCO Annual Meeting, Disc will present updated data from the Phase 2 trial of DISC-0974 in 61 patients with MF anemia, which is expected to enhance the company's influence in the oncology space and prepare for subsequent FDA meetings.
- Strong Financial Position: As of March 31, 2026, Disc's cash and cash equivalents totaled approximately $730 million, projected to fund operations into 2029, demonstrating robust financial resilience that supports ongoing R&D initiatives.
- Increased R&D Spending: The R&D expenses for Q1 2026 were $45.9 million, significantly up from $27.8 million in Q1 2025, reflecting strategic investments in advancing clinical trials and expanding the team, despite resulting in a net loss of $63.5 million.
See More
Disc Medicine Q1 Earnings Beat Expectations Amid Restructuring
- Earnings Performance: Disc Medicine reported a Q1 GAAP EPS of -$1.65, beating market expectations by $0.04, indicating some improvement in financial management despite ongoing losses.
- Cash Reserves: As of March 31, 2026, the company held $730.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operational plans into 2029, ensuring continued operational capability over the next few years.
- Restructuring Plan: The company is undergoing a restructuring plan that involves a 20% workforce reduction aimed at lowering operational costs and improving efficiency, which may impact employee morale in the short term but is intended to enhance long-term survival and growth in a competitive market.
- Regulatory Challenges: Disc Medicine faces challenges from the FDA's Complete Response Letter, casting doubt on the APOLLO study's prospects, which could affect future drug approval processes and increase uncertainty for investors.
See More
Disc Medicine Faces Securities Claims Investigation by Rosen Law Firm
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact stock prices and investor confidence.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application for its bitopertin program, citing the need for additional evidence to resolve uncertainties, which led to a 22% drop in stock price that day, reflecting market concerns about the company's product prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing affected investors to seek compensation without any out-of-pocket costs, a move that may attract more investors and intensify the legal pressure on the company.
- Law Firm's Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases, which could significantly influence the legal outcomes for Disc Medicine.
See More
Pomerantz LLP Investigates Claims for Disc Medicine Investors
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- FDA Review Delay: On January 15, 2026, Disc's drug development faced a delay in review after FDA scientists flagged safety and efficacy concerns, resulting in a stock price drop of $6.04, or 7.84%, closing at $71.04, indicating market apprehension regarding the company's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its new drug application for bitopertin, stating that trials did not demonstrate efficacy related to sunlight exposure, causing the stock to plummet by $15.70, or 21.91%, to close at $55.95, reflecting investor disappointment in the drug's future.
- Law Firm Background: Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, showcasing its authority and influence in the legal field.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ:IRON) for allegedly issuing misleading business information, and investors who purchased securities may be entitled to compensation without any out-of-pocket costs.
- FDA Application Rejection: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine to recover investor losses, with investors encouraged to join the action through their website or by phone.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong reputation and success in this field.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine, Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could undermine investor confidence and the company's reputation.
- FDA Review Delay: On January 15, 2026, a drug under development by Disc faced a review delay after FDA scientists flagged safety and efficacy concerns, resulting in a 7.84% drop in stock price to $71.04 per share, reflecting market apprehension about the product's prospects.
- Complete Response Letter: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its new drug application for bitopertin, stating that trials did not demonstrate an association between PPIX changes and sunlight exposure, causing a further 21.91% decline in stock price to $55.95 per share, indicating heightened regulatory risks.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, and if the investigation confirms fraudulent activities, the company could face substantial damages, further impacting its market performance.
See More
Disc Medicine Completes Enrollment in Phase 3 APOLLO Study
- Clinical Trial Progress: Disc Medicine has completed enrollment of 183 patients in the Phase 3 APOLLO trial for EPP, with topline data expected in Q4 2026, a move that not only meets patient and physician demand but also lays the groundwork for future FDA submissions.
- ASCO Presentation: At the upcoming ASCO Annual Meeting, Disc will present updated data from the Phase 2 trial of DISC-0974 in 61 patients with MF anemia, which is expected to enhance the company's influence in the oncology space and prepare for subsequent FDA meetings.
- Strong Financial Position: As of March 31, 2026, Disc's cash and cash equivalents totaled approximately $730 million, projected to fund operations into 2029, demonstrating robust financial resilience that supports ongoing R&D initiatives.
- Increased R&D Spending: The R&D expenses for Q1 2026 were $45.9 million, significantly up from $27.8 million in Q1 2025, reflecting strategic investments in advancing clinical trials and expanding the team, despite resulting in a net loss of $63.5 million.
See More
Disc Medicine Q1 Earnings Beat Expectations Amid Restructuring
- Earnings Performance: Disc Medicine reported a Q1 GAAP EPS of -$1.65, beating market expectations by $0.04, indicating some improvement in financial management despite ongoing losses.
- Cash Reserves: As of March 31, 2026, the company held $730.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operational plans into 2029, ensuring continued operational capability over the next few years.
- Restructuring Plan: The company is undergoing a restructuring plan that involves a 20% workforce reduction aimed at lowering operational costs and improving efficiency, which may impact employee morale in the short term but is intended to enhance long-term survival and growth in a competitive market.
- Regulatory Challenges: Disc Medicine faces challenges from the FDA's Complete Response Letter, casting doubt on the APOLLO study's prospects, which could affect future drug approval processes and increase uncertainty for investors.
See More
Disc Medicine Faces Securities Claims Investigation by Rosen Law Firm
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact stock prices and investor confidence.
- FDA Rejection of NDA: On February 13, 2026, the FDA issued a Complete Response Letter rejecting Disc Medicine's new drug application for its bitopertin program, citing the need for additional evidence to resolve uncertainties, which led to a 22% drop in stock price that day, reflecting market concerns about the company's product prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing affected investors to seek compensation without any out-of-pocket costs, a move that may attract more investors and intensify the legal pressure on the company.
- Law Firm's Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases, which could significantly influence the legal outcomes for Disc Medicine.
See More
Pomerantz LLP Investigates Claims for Disc Medicine Investors
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- FDA Review Delay: On January 15, 2026, Disc's drug development faced a delay in review after FDA scientists flagged safety and efficacy concerns, resulting in a stock price drop of $6.04, or 7.84%, closing at $71.04, indicating market apprehension regarding the company's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its new drug application for bitopertin, stating that trials did not demonstrate efficacy related to sunlight exposure, causing the stock to plummet by $15.70, or 21.91%, to close at $55.95, reflecting investor disappointment in the drug's future.
- Law Firm Background: Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, showcasing its authority and influence in the legal field.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ:IRON) for allegedly issuing misleading business information, and investors who purchased securities may be entitled to compensation without any out-of-pocket costs.
- FDA Application Rejection: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine to recover investor losses, with investors encouraged to join the action through their website or by phone.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong reputation and success in this field.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine, Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could undermine investor confidence and the company's reputation.
- FDA Review Delay: On January 15, 2026, a drug under development by Disc faced a review delay after FDA scientists flagged safety and efficacy concerns, resulting in a 7.84% drop in stock price to $71.04 per share, reflecting market apprehension about the product's prospects.
- Complete Response Letter: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its new drug application for bitopertin, stating that trials did not demonstrate an association between PPIX changes and sunlight exposure, causing a further 21.91% decline in stock price to $55.95 per share, indicating heightened regulatory risks.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, and if the investigation confirms fraudulent activities, the company could face substantial damages, further impacting its market performance.
See More
